Pneumococcal conjugate second or third-dose vaccines (PCVc) in Papua New Guinea
Papua New Guinea: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 44.0% in 2025. β Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Papua New Guinea, 2008β2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, pneumococcal conjugate second or third-dose vaccines (pcvc) in Papua New Guinea stood at 44.0%. That is the highest value across all 18 years on record.
The figure is up 7.3% on the previous year and up 120.0% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Papua New Guinea peaked at 44.0% in 2025 and was at its lowest, 0.0%, in 2008.
That places Papua New Guinea 157th out of 192 countries with data for 2025, putting it in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 14.6% | 0.0% | 36.0% | 10 |
| 2020s | 37.8% | 29.0% | 44.0% | 6 |
Countries ranked near Papua New Guinea
- 154 Kazakhstan, Republic of 49.0% compare
- 154 Chad 49.0% compare
- 156 Central African Republic 45.0% compare
- 158 Haiti 39.0% compare
- 158 Yemen, Republic of 39.0% compare
- 160 Montenegro 28.0% compare
More health data for Papua New Guinea
- Un projection of annual infant deaths, annual growth rate -1.77 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.3741 % change on previous year (2090)
- Heat deaths vs projected death rates 1,127 (2090)
- Un projection of annual infant deaths 2,501 (2100)
- Deaths in armed conflicts by country 0 (2026)
- Deaths in armed conflicts by region 0 (2026)
- Age population, age 25, male, interpolated 97,965 (2025)
- Age population, age 25, female, interpolated 89,573 (2025)
- Age population, age 24, male, interpolated 99,735 (2025)
- Age population, age 24, female, interpolated 90,833 (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Papua New Guinea?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Papua New Guinea was 44.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Papua New Guinea?
- The highest recorded value was 44.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Papua New Guinea?
- The lowest recorded value was 0.0% in 2008.
- How does Papua New Guinea rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Papua New Guinea ranks 157th out of 192 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Papua New Guinea?
- Over the last ten years it is up 120.0%. The long-run trend across the full record is volatile.
- Where does this Papua New Guinea data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV Β· JSON β 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).